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fatty acids. The major precursor Arachidonic acid (all-cis-5,8,11,14-
eicosatetraenoic acid) is metabolized to prostaglandins (PG) and prosta-
cyclin (PGI) by the cyclooxygenase (COX) pathway, while leukotri-
enes are formed via the lipoxygenase (LOX) pathway. These down 
stream lipid metabolites are thought to be involved in carcinogenesis, 
and ample preclinical ﬁndings support modulations of arachidonic acid 
pathways for inhibition of carcinogenesis. There are two main isoforms 
of COX: COX-1 and COX-2. COX-1 exists in most cells and is consti-
tutively active. In contrast, COX-2 is an inducible enzyme that is up-
regulated by carcinogens, inﬂammatory and mitogenic stimuli. COX-2 
is primarily responsible for the overproduction of PG in inﬂamed, as 
well as neoplastic tissues. Overproduction of PGE2 is associated with 
a variety of carcinogenic mechanism, including abnormal expression 
of epithelial growth factors, epithelial and microvascular proliferation, 
resistance to apoptosis and inhibition of antitumor immunity.
COX-2 expression has been demonstrated in premalignant bronchial 
tissue and lung cancer. Patients with higher levels of COX-2 expres-
sion in their tumors have a poorer prognosis. In murine models, COX-2 
inhibition impedes lung tumorigenesis, decreases the rate of growth of 
lung cancer and number and size of metastasis. Expression of COX-2 
has been shown to enhance tumorigenesis by regulation of angiogen-
esis via CXC chemokines and EGFR, invasion via CD44 and matrix 
metalloproteinases, apoptosis via survivin and insulin like growth 
factor, and anti-tumor immunity via IL-10 and IL-12. Several clini-
cal trials addressing the use of Celecoxib for lung cancer prevention 
are underway. Results of a pilot, phase IIa trial in high-risk smokers 
performed at UCLA suggest that Celecoxib may modulate SEBM with 
reduction of PGE2 production, restoration of anti-tumor immunity and 
reduction of proliferation indices (Ki-67 labeling index). A follow-up 
larger phase IIb trial focusing on heavy former smokers is evaluating 
the effect of Celecoxib on cellular and molecular events associated with 
lung carcinogenesis. Another phase IIb trial of Celecoxib in current and 
former smokers is being conducted at MD Anderson Cancer Center. 
Moreover, A multicenter study with the lead center at Mayo Clinic us-
ing Sulindac, a nonspeciﬁc COX inhibitor, is also recruiting patients. 
5-lipooxygenase (LOX) is an enzyme involved in the conversion of 
arachidonic acid to leukotrienes. Leukotrienes have been implicated to 
play a prominent inductive role in lung carcinogenesis. This is based on 
data demonstrating that 5-LOX is expressed in lung cancers and 5-LOX 
inhibitors reduced the multiplicity and incidence of lung tumors in 
mice. A Phase II Clinical trial of the 5-LOX inhibitor Zileuton has been 
conducted at the Karmanos Cancer Institute addressing the effect of 
Zileuton on bronchial dysplasia and multiple SEBM in at-risk smokers 
or patients with curatively treated aerodigestive cancers.
Another arachidonic acid metabolite of interest is prostacyclin (PGI). 
It has been demonstrated that up-regulation of PGI decreased tumori-
genicity in mice exposed to carcinogens. A multicenter study with the 
lead center at the University of Colorado is currently enrolling smokers 
and ex-smokers with sputum atypia in a phase II randomized clinical 
trial to evaluate the effectiveness of Iloprost, a synthetic analog of PGI. 
Endpoints include comparisons of phenotypic modulation of bronchial 
epithelium between the two groups, as well as evaluation of multiple 
SEBM. 
Numerous clinical studies evaluating promising agents in lung cancer 
chemoprevention are underway. Important goals for future chemopre-
vention trials include devising strategies to minimize toxicity, identify 
and validate appropriate SEBM. To this end, integration of new diag-
nostic technologies such as ﬂuorescence bronchscopy and spiral CT, 
molecular proﬁling of risks, using high-throughput technology such 
as genomics microarray and proteomics, for therapeutic stratiﬁcation 
and monitoring, will collectively facilitate the development of effective 
paradigms for prevention, early detection and treatment of lung cancer. 
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Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) given concurrently with chemotherapy do not improve patient 
outcomes compared to chemotherapy alone in advanced non-small cell 
lung cancer (NSCLC). One potential explanation for this lack of beneﬁt 
is a negative interaction or antagonism between chemotherapy and 
EGFR TKIs when delivered concomitantly. Support for this line of rea-
soning is provided by preclinical data demonstrating that EGFR TKIs 
induce primarily a cytostatic effect resulting from a G1 cell cycle arrest 
in cell lines with wild type (WT) EGFR, reducing cell cycle phase-de-
pendent activity of chemotherapy, whereas they induce apoptotic cell 
death in tumors with EGFR activating mutations. Thus, sequence-spe-
ciﬁc interactions of EGFR TKI-chemotherapy combinations may nega-
tively inﬂuence the efﬁcacy of these regimens in patients with NSCLC. 
Preclinical and clinical rationale for studies examining the concept of 
pharmacodynamic separation as a means for overcoming hypothesized 
antagonism of EGFR TKIs and chemotherapy as well as recent clinical 
trial results will be discussed.
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In the last years the identiﬁcation of a number of molecular targets 
essential and speciﬁc for tumor growth, cell proliferation and metas-
tasis development has produced a new class of anticancer drugs, the 
molecular targeted therapies.
Molecular biology has clearly identiﬁed many different tumoral meta-
bolic pathways which are active and crucial to neoplastic phenotype 
across different histologic solid tumors. Among these, the HER family 
receptors and neoangiogenesis have been particularly studied and a 
number of new drugs that inhibit speciﬁc growth factors such as epi-
dermal growth factors (EGF) and vascular endothelial growth factors 
(VEGF) have been developed through phase I-II-III trials as single 
agents or in combination with chemotherapy and some have been 
already registered for the treatment of advanced Non Small Cell Lung 
Cancer (NSCLC).
Among many factors related in promoting angiogenesis, Vascular 
Endothelial Growth Factor (VEGF) has a recognized critical rate-limit-
ing role because of its ability to regulate key steps in the angiogenesis 
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cascade, such as endothelial cell proliferation, migration, survival and 
capillary formation (1).
Vandetanib (ZD6474, Zactima) is a novel anilinoquinazoline which 
has shown activity as a potent and reversible inhibitor of VEGFR-2 
tyrosine kinase. It is a small molecule with good oral bioavailability 
and constant plasma drug levels. 
Furthermore, vandetanib also inhibits epidermal growth factor receptor 
tyrosine kinase activity combining activity against neoangiogenesis and 
signal transduction pathway (2).
Vandetanib has shown inhibition of tumor cell growth in a broad range 
of preclinical models including lung cancer xenografts after oral ad-
ministration with an acceptable preclinical toxicology proﬁle.
It was possible to demonstrate inhibition by vandetanib of EGF-stumu-
lated cell proliferation and inhibition of both VEGFR and EGFR tyro-
sine kinase in vitro, and preclinical models have shown activity against 
NSCLC xenografts (3). 
Vandetanib (ZACTIMA™; ZD6474) is a once-daily oral anticancer drug 
at the moment in phase III clinical development in a broad population of 
patients with advanced NSCLC. Vandetanib targets clinically validated 
signaling pathways in NSCLC by inhibiting VEGFR-dependent tumor 
angiogenesis and EGFR-dependent tumor growth and survival. Vande-
tanib also inhibits RET kinase activity, which is an important growth 
driver in certain types of thyroid cancer. 
Phase I evaluation in patients with advanced solid tumors showed 
vandetanib was generally well tolerated at daily oral doses of ≤300 mg. 
Common adverse events included rash, diarrhea and asymptomatic QTc 
prolongation, all of which were controlled by standard management. A 
series of randomized, double-blind Phase II studies have investigated the 
efﬁcacy of vandetanib in NSCLC, both as monotherapy and in com-
bination with certain chemotherapies. A two-part study (6474IL0003) 
compared vandetanib 300 mg with geﬁtinib (IRESSA™; 250 mg) in 
2nd/3rd-line NSCLC; in part B, eligible patients had the option to switch 
to the alternative treatment. The study achieved its primary efﬁcacy 
objective: median progression-free survival (PFS) in part A was 11 
weeks for vandetanib versus 8 weeks for geﬁtinib (hazard ratio = 0.69, 
95% CI = 0.50-0.96; 1-sided P = 0.013). In 2nd-line NSCLC, vandetanib 
(100 or 300 mg) or placebo was assessed in combination with docetaxel 
(6474IL0006). This study also achieved its primary objective, with 
vandetanib 100 mg + docetaxel demonstrating a signiﬁcant prolongation 
of PFS versus docetaxel alone (hazard ratio =0.64, 95% CI = 0.38-
1.05; 1-sided P = 0.037). In 1st-line NSCLC, vandetanib (300 mg/day) 
± carboplatin and paclitaxel (CP) was compared with CP + placebo 
(6474IL0007). The primary objective was met, with vandetanib + CP 
prolonging PFS versus CP alone (hazard ratio = 0.76, 95% CI = 0.50-
1.15; 1-sided P = 0.098): median PFS was 24 weeks (vandetanib + CP) 
and 23 weeks (CP). The vandetanib monotherapy arm was stopped early 
after a planned interim PFS analysis met the criterion for discontinuation 
(hazard ratio >1.33 versus CP). In all three studies, no overall survival 
beneﬁt with vandetanib was seen. However, overall survival was a sec-
ondary endpoint in these studies and the effect of vandetanib on survival 
is potentially confounded by the impact of post-progression therapies.
The positive outcomes from these phase II studies have led to the 
initiation of phase III evaluation of vandetanib in a broad population 
of patients with advanced NSCLC, including squamous and non-squa-
mous cell histology. There are four phase III trials in NSCLC currently 
recruiting patients: vandetanib 300 mg versus placebo in patients previ-
ously treated with anti-EGFR therapy (6474IL0044); vandetanib 300 
mg versus erlotinib in refractory NSCLC (6474IL0057); vandetanib 
100 mg + docetaxel versus placebo + docetaxel in 2nd-line NSCLC 
(6474IL0032); and vandetanib 100 mg + pemetrexed versus placebo + 
pemetrexed in 2nd-line NSCLC (6474IL0036). 
A randomized phase III trial comparing carboplatin paclitaxel and van-
detanib vs the same chemotherapy alone, has been recently completed 
in 300 patients.
Clinical development is also ongoing in other tumor types, including 
hereditary medullary thyroid cancer, where encouraging antitumor 
activity has been observed.
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Introduction
To date, the glucose analogue 18FDG still is the best PET tracer for 
staging of lung cancer. Experiments with thymidine-analogues, choline 
etc. have not revealed diagnostic superiority in terms of TNM staging. 
Moreover, the conceptually present biological (i.e. prognostic) value of 
tracers like 18FLT has not yet been elucidated. 
At the crossroads of tomographic imaging and intervention, the 
introduction of PET-CT and the increased application of non-surgical 
therapeutic modalities are the main developments in the past decade. 
PET(-CT) and staging
The diagnostic accuracy of PET needs to be stratiﬁed for nodal size at 
CT [1]. In meta-analysis the pooled sensitivity of PET to identify ≥N2 
stage in patients with non-enlarged nodes, was 0.75 (95%CI: 0.59-
0.87); in combination with pre-test probability of N2 in this situation 
[2], it is predicted that the negative predictive value of PET is about 
94%. Hence, even if invasive preoperative staging procedures would 
have a sensitivity of 100% (which is clearly not the case), at least 16 
invasive procedures would be required to identify a single patient with 
N2 disease. More recent studies conﬁrm that the yield of invasive 
staging procedures in patients with normal-sized and FDG-PET nega-
tive nodes is indeed extremely low [3]. In the meta-analysis of Gould 
et al, the sensitivity of PET in patients with enlarged nodes was 0.91 
(95%CI .79-.96). It is likely that this 16% lower sensitivity of PET (vs. 
non-enlarged nodes) is caused by partial volume effects with smaller 
tumor deposits (the typical post-reconstruction resolution of PET being 
about 5-7 mm). Above the centimeter limit, these effects are much less 
likely to affect diagnostic performance. The prevalence of malignancy 
in mediastinal nodes [4] with 10-15mm short axis diameters is 0.29 
(95%CI 0.23-0.36), vs. 0.68 (95%CI 0.52-0.81) for nodes of 16-20 
mm (i.e. similar to even larger nodes). Reasoning that partial volume 
effects are irrelevant with deposits > 10 mm, one can predict that the 
post-test probability of N2 disease in patients with 10-15mm nodes and 
